Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 17/20 | 0.50 |
| ▸ | CTRC | Q99895 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7676592 | 0.93 | F2 (0.49) | F2CTRCPRSS2F10TDP1 | |
| Hydrochloric Acid SCHEMBL6747655 | 0.92 | F2 (0.48) | F2CTRCPRSS2F10TDP1 | |
| SCHEMBL7646675 | 0.92 | F2 (0.48) | F2CTRCPRSS2F10 | |
| Hydrochloric Acid SCHEMBL6749567 | 0.91 | F2 (0.47) | F2CTRCPRSS2F10 | |
| SCHEMBL6747388 | 0.88 | F2 (0.52) | F2CTRCPRSS2F10 | |
| SCHEMBL6747898 | 0.87 | F2 (0.66) | F2PRSS2 | |
| SCHEMBL6750744 | 0.85 | F2 (0.47) | F2CTRCPRSS2F10 | |
| Hydrochloric Acid SCHEMBL6745864 | 0.84 | F2 (0.47) | F2CTRCPRSS2F10 | |
| Hydrochloric Acid SCHEMBL6747748 | 0.84 | F2 (0.49) | F2CTRCPRSS2F10 | |
| SCHEMBL6746098 | 0.82 | F2 (0.43) | F2CTRCPRSS2F10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730783-B2 | REACTING AMINOGUANIDINE WITH CARBONYL COMPOUND TO FORM AMIDINOHYDRAZONE; REDUCTION; REACTING WITH ALKOXYAMINE; GUANIDINYLATION; ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6706765-B2 | ESPECIALLY TRYPSIN-LIKE SERINE PROTEASES, SUCH AS CHYMOTRYPSIN, TRYPSIN, THROMBIN, PLASMIN AND FACTOR XA. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-6638931-B1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| US-6235778-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | F2 27/4885CTRC 69/4885HTT 2344/4885 |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | PLG, MMP9, F9 | F2 27/4885CTRC 112/4885HTT 2560/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | F2 32/4885CTRC 91/4885HTT 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.